• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy.

作者信息

Li Siqi, Tajiri Kazuko

机构信息

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Japan.

出版信息

Intern Med. 2021 Feb 1;60(3):325-326. doi: 10.2169/internalmedicine.5962-20. Epub 2020 Sep 19.

DOI:10.2169/internalmedicine.5962-20
PMID:32963172
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7925265/
Abstract
摘要

相似文献

1
A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy.免疫检查点抑制剂治疗心脏并发症的生物标志物缺失
Intern Med. 2021 Feb 1;60(3):325-326. doi: 10.2169/internalmedicine.5962-20. Epub 2020 Sep 19.
2
Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.纳武单抗和伊匹单抗诱发的肌炎和心肌炎，表现类似重症肌无力。
Neuromuscul Disord. 2020 Jan;30(1):67-69. doi: 10.1016/j.nmd.2019.10.006. Epub 2019 Nov 4.
3
Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.与纳武单抗治疗黑色素瘤相关的皮肌炎：一例病例报告及文献综述
Dermatol Online J. 2020 Aug 15;26(8):13030/qt4c21b068.
4
New biomarker-based strategy screens for myocarditis after immune checkpoint inhibitor treatment.
Cancer. 2023 May 1;129(9):1304. doi: 10.1002/cncr.34777.
5
[Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].[抗程序性死亡蛋白1治疗期间发生心肌炎时的三度房室传导阻滞：病例报告及文献综述]
Rev Med Interne. 2020 Apr;41(4):284-288. doi: 10.1016/j.revmed.2019.12.023. Epub 2020 Jan 23.
6
Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.免疫检查点抑制剂相关性肺毒性：聚焦纳武利尤单抗。
South Med J. 2020 Nov;113(11):600-605. doi: 10.14423/SMJ.0000000000001166.
7
An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer.纳武利尤单抗致胃癌晚期暴发性心肌炎 1 例尸检报告
Intern Med. 2022 Oct 1;61(19):2867-2871. doi: 10.2169/internalmedicine.9161-21. Epub 2022 Mar 5.
8
Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.尼妥珠单抗联合 PROSTVAC 治疗后发生心肌炎 1 例报告
J Immunother Cancer. 2018 Dec 18;6(1):150. doi: 10.1186/s40425-018-0473-0.
9
Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view.免疫检查点抑制剂与预先存在的抗核抗体：风湿病学家的观点
Clin Transl Oncol. 2021 Sep;23(9):1961-1962. doi: 10.1007/s12094-021-02584-y. Epub 2021 Mar 17.
10
A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.1例转移性黑色素瘤患者因免疫检查点抑制剂诱发的过敏性紫癜。
Eur J Cancer. 2020 Nov;139:169-172. doi: 10.1016/j.ejca.2020.08.005. Epub 2020 Sep 29.

引用本文的文献

1
The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors.免疫检查点抑制剂的益处（肿瘤杀伤）与弊端（心血管并发症）
Curr Cardiol Rep. 2024 Dec;26(12):1487-1498. doi: 10.1007/s11886-024-02147-x. Epub 2024 Oct 23.
2
Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors.克服癌症治疗免疫检查点抑制剂的心脏毒性。
Front Oncol. 2022 Sep 16;12:940127. doi: 10.3389/fonc.2022.940127. eCollection 2022.
3
Programmed Death-Ligand 2 Deficiency Exacerbates Experimental Autoimmune Myocarditis in Mice.程序性死亡配体 2 缺乏加剧了小鼠实验性自身免疫性心肌炎。
Int J Mol Sci. 2021 Jan 31;22(3):1426. doi: 10.3390/ijms22031426.

本文引用的文献

1
The Cytokine Expression in Patients with Cardiac Complication after Immune Checkpoint Inhibitor Therapy.免疫检查点抑制剂治疗后并发心脏并发症患者的细胞因子表达。
Intern Med. 2021 Feb 1;60(3):423-429. doi: 10.2169/internalmedicine.5317-20. Epub 2020 Sep 19.
2
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment.免疫检查点抑制剂相关性心肌炎：病理生理特征、诊断与治疗
J Am Heart Assoc. 2020 Jan 21;9(2):e013757. doi: 10.1161/JAHA.119.013757.
3
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.免疫检查点抑制剂介导的肿瘤反应和不良事件的生物标志物
Front Med (Lausanne). 2019 May 29;6:119. doi: 10.3389/fmed.2019.00119. eCollection 2019.
4
Cardiac Complications in Immune Checkpoint Inhibition Therapy.免疫检查点抑制疗法中的心脏并发症
Front Cardiovasc Med. 2019 Jan 23;6:3. doi: 10.3389/fcvm.2019.00003. eCollection 2019.
5
Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer.皮肤癌中检查点抑制剂治疗反应的细胞因子、趋化因子及其他生物标志物
Front Med (Lausanne). 2018 Dec 12;5:351. doi: 10.3389/fmed.2018.00351. eCollection 2018.
6
Immune checkpoint inhibitor-related myocarditis.免疫检查点抑制剂相关心肌炎
Jpn J Clin Oncol. 2018 Jan 1;48(1):7-12. doi: 10.1093/jjco/hyx154.
7
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.血清白细胞介素-8（IL-8）水平的变化反映并预测了抗 PD-1 治疗对黑色素瘤和非小细胞肺癌患者的疗效。
Ann Oncol. 2017 Aug 1;28(8):1988-1995. doi: 10.1093/annonc/mdx190.
8
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.与 CTLA4 和 PD1 阻断免疫疗法相关的心脏毒性。
J Immunother Cancer. 2016 Aug 16;4:50. doi: 10.1186/s40425-016-0152-y. eCollection 2016.
9
The interleukin-8 pathway in cancer.癌症中的白细胞介素-8信号通路。
Clin Cancer Res. 2008 Nov 1;14(21):6735-41. doi: 10.1158/1078-0432.CCR-07-4843.